Janice MacLennan, pharma strategy consultant and founder & CEO, Nmblr answers the question: will 2026 signal the end of business-as-usual in biopharma commercialisation?
Nmblr
Recalibrate or retreat: the end of business-as-usual in biopharma commercialisation
Janice MacLennan, pharma strategy consultant and founder & CEO, Nmblr answers the question: will 2026 signal the end of business-as-usual in biopharma commercialisation?
Published:
|
7 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.